Shares of Sellas Life Sciences SLS surged more than 220% at market open on Tuesday after the drug developer reported positive results from a late-stage trial of its experimental cancer vaccine, which significantly extended survival among patients with acute myeloid leukemia (AML).
The vaccine, called galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in a study involving 126 patients, the company said.
Patients who received GPS recorded a median overall survival of 24 months, against 14.7 months among those in the control group.
Trading in Sellas shares was halted during premarket hours following the sharp rise.
Vaccine shows survival benefit in AML patients
The trial evaluated GPS in patients with AML who had achieved remission following cancer treatment but were unable to undergo a bone marrow or stem cell transplant.
AML is an aggressive cancer affecting the blood and bone marrow.
Patients whose disease returns after treatment often have limited therapeutic options, making the development of treatments that can prolong survival particularly important.
GPS is designed to train the immune system to identify and attack residual leukemia cells carrying a protein known as WT1.
Sellas said the vaccine was generally well tolerated and did not raise any new safety concerns.
Most reported side effects were mild to moderate, with injection-site reactions being the most common.
“The magnitude of the survival benefit observed with our investigational GPS immunotherapeutic cancer vaccine represents a defining milestone for Sellas,” CEO Angelos Stergiou said.
The scale of the potential patient population is significant.
According to the American Cancer Society, about 22,720 people in the US are expected to be diagnosed with AML in 2026, while approximately 11,500 are projected to die from the disease, Reuters reported.
AML accounts for one in three adult leukemia cases.
Sellas targets FDA discussions and 2027 filing
Sellas plans to meet with the US Food and Drug Administration (FDA) to discuss the trial findings and an accelerated regulatory strategy.
The company is preparing for a Biologics License Application (BLA) submission in the first half of 2027.
“Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible,” Stergiou said.
The regulatory discussions will be an important next step as the company seeks to translate the trial results into a potential treatment option.
The findings do not, however, mean that GPS has received regulatory approval.
Company advances another leukemia drug candidate
The latest development comes as Sellas continues to advance its broader oncology pipeline.
Earlier this month, the company reported a net loss of $10.1 million, or $0.05 per share, compared with a loss of $6.8 million, or $0.06 per share, a year earlier.
Sellas reported no revenue, in line with analyst expectations.
Its smaller loss per share came despite the increase in its overall loss, as weighted-average shares outstanding rose to approximately 202.4 million from 108.4 million.
Last week, Sellas also said that 40 patients had enrolled in an 80-patient Phase 2 trial of tambiciclib, also known as SLS009, in newly diagnosed AML.
Preliminary results are expected in the fourth quarter.
Separately, the company plans to present completed Phase 2 findings for SLS009 in relapsed or refractory leukemia at the American Society of Hematology meeting in December.
Sellas has reported response rates of 54% among patients with monocytic disease and 57% among those with TP53-mutated disease.
The GPS results have given Sellas a significant clinical milestone, although the company’s next challenge will be securing a regulatory pathway for the vaccine and demonstrating that the survival benefit can support its eventual approval.
AI disclosure: AI tools assisted with research and drafting of this piece. An Invezz editor reviewed the facts, sources and wording before publication. Any opinions or analysis are Invezz’s, not those of an automated system.
The post Why is SLS stock soaring over 220% on Tuesday? appeared first on Invezz
